Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach?
作者信息
Andó Giuseppe, Costa Francesco
机构信息
Department of Clinical and Experimental Medicine, Section of Cardiology, University of Messina, Messina, Italy.
出版信息
Postepy Kardiol Interwencyjnej. 2015;11(3):170-3. doi: 10.5114/pwki.2015.54007. Epub 2015 Sep 28.
Abstract
摘要
相似文献
1
Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach?
Postepy Kardiol Interwencyjnej. 2015;11(3):170-3. doi: 10.5114/pwki.2015.54007. Epub 2015 Sep 28.
2
Bleeding risk stratification in an era of aggressive management of acute coronary syndromes.
World J Cardiol. 2014 Nov 26;6(11):1140-8. doi: 10.4330/wjc.v6.i11.1140.
3
Stenting in acute coronary syndromes: a comparison of radial versus femoral access sites.
J Am Coll Cardiol. 1998 Sep;32(3):572-6. doi: 10.1016/s0735-1097(98)00288-5.
4
Radial vs Femoral Approach in Acute Coronary Syndromes: A Meta- Analysis of Randomized Trials.
Curr Vasc Pharmacol. 2017;16(1):79-92. doi: 10.2174/1570161115666170504125831.
5
Transradial versus transfemoral percutaneous coronary intervention in acute coronary syndromes: re-evaluation of the current body of evidence.
JACC Cardiovasc Interv. 2013 Nov;6(11):1149-52. doi: 10.1016/j.jcin.2013.08.003.
6
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy.
Am Heart J. 2013 Apr;165(4):583-590.e1. doi: 10.1016/j.ahj.2013.01.009. Epub 2013 Feb 22.
7
Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial.
Lancet. 2015 Jun 20;385(9986):2465-76. doi: 10.1016/S0140-6736(15)60292-6. Epub 2015 Mar 16.
8
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.
Lancet. 2011 Apr 23;377(9775):1409-20. doi: 10.1016/S0140-6736(11)60404-2. Epub 2011 Apr 4.
9
Radial Access Reduces Mortality in Patients With Acute Coronary Syndromes: Results From an Updated Trial Sequential Analysis of Randomized Trials.
JACC Cardiovasc Interv. 2016 Apr 11;9(7):660-70. doi: 10.1016/j.jcin.2015.12.008.
10
Acute kidney injury after percutaneous coronary intervention: Rationale of the AKI-MATRIX (acute kidney injury-minimizing adverse hemorrhagic events by TRansradial access site and systemic implementation of angioX) sub-study.
Catheter Cardiovasc Interv. 2015 Nov;86(5):950-7. doi: 10.1002/ccd.25932. Epub 2015 Apr 9.
引用本文的文献
1
Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions.
J Clin Med. 2019 Nov 19;8(11):2016. doi: 10.3390/jcm8112016.
2
The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short.
Cardiovasc Diagn Ther. 2018 Oct;8(5):630-646. doi: 10.21037/cdt.2018.10.01.
3
Factors affecting treatment, management and mortality in cases of retroperitoneal hematoma after cardiac catheterization: a single-center experience.
Postepy Kardiol Interwencyjnej. 2017;13(3):218-224. doi: 10.5114/aic.2017.70189. Epub 2017 Sep 25.
4
The ACEF (age, creatinine, ejection fraction) score predicts ischemic and bleeding outcomes of patients with acute coronary syndromes treated conservatively.
Postepy Kardiol Interwencyjnej. 2017;13(2):160-164. doi: 10.5114/pwki.2017.68209. Epub 2017 Jun 8.
5
Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation.
Postepy Kardiol Interwencyjnej. 2016;12(4):290-302. doi: 10.5114/aic.2016.63626. Epub 2016 Nov 17.
本文引用的文献
1
Accuracy of bleeding scores for patients presenting with myocardial infarction: a meta-analysis of 9 studies and 13 759 patients.
Postepy Kardiol Interwencyjnej. 2015;11(3):182-90. doi: 10.5114/pwki.2015.54011. Epub 2015 Sep 28.
2
Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration.
EuroIntervention. 2016 Feb;11(11):e1222-30. doi: 10.4244/EIJY15M08_04.
3
Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey.
EuroIntervention. 2015 May;11(1):68-74. doi: 10.4244/EIJV11I1A11.
4
Radial Versus Femoral Access for Coronary Angiography/Intervention in Women With Acute Coronary Syndromes: Insights From the RIVAL Trial (Radial Vs femorAL access for coronary intervention).
JACC Cardiovasc Interv. 2015 Apr 20;8(4):505-12. doi: 10.1016/j.jcin.2014.11.017.
5
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials.
BMJ. 2015 Apr 16;350:h1618. doi: 10.1136/bmj.h1618.
6
Acute kidney injury after percutaneous coronary intervention: Rationale of the AKI-MATRIX (acute kidney injury-minimizing adverse hemorrhagic events by TRansradial access site and systemic implementation of angioX) sub-study.
Catheter Cardiovasc Interv. 2015 Nov;86(5):950-7. doi: 10.1002/ccd.25932. Epub 2015 Apr 9.
7
Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial.
Lancet. 2015 Jun 20;385(9986):2465-76. doi: 10.1016/S0140-6736(15)60292-6. Epub 2015 Mar 16.
8
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.
J Am Coll Cardiol. 2015 May 26;65(20):2211-21. doi: 10.1016/j.jacc.2015.03.003. Epub 2015 Mar 15.
9
Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?
Eur Heart J. 2015 May 21;36(20):1219-22. doi: 10.1093/eurheartj/ehv053. Epub 2015 Mar 11.
10
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
Eur Heart J. 2015 May 21;36(20):1242-51. doi: 10.1093/eurheartj/ehv038. Epub 2015 Feb 25.
Zotero 插件